MiMedx posts record Q4 sales $118M (+27% YoY); 2026 guidance $340-360M; $100M buyback

MIMEDX GROUP, INC.

2025-FY EPS reported $0.32 revenue$418,630,000

Q4 net sales $118M, +27% YoY; full-year $419M, +20% YoY.
Q4 GAAP net income $15M ($0.10 EPS); Adjusted EBITDA $29M (25% margin).
2026 net sales guidance $340-360M, down from 2025 actual; Adj EBITDA margin mid-to-high teens.
Board authorizes $100M share repurchase program over two years.
Cash & equivalents $166M; net cash $148M; SG&A up 18% to $266M on higher commissions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.